Stock Scorecard



Stock Summary for LivaNova PLC (LIVN) - $52.15 as of 10/8/2025 4:17:17 PM EST

Total Score

10 out of 30

Safety Score

45 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LIVN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LIVN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LIVN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LIVN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LIVN (45 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 4
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for LIVN

Nyxoah Expands in the Middle East to Provide Wider Access to Genio 10/2/2025 1:10:00 PM
Neuromodulation Market is expected to generate a revenue of USD 9.32 Billion by 2032, Globally, at 9.27% CAGR: Verified Market Research® 9/18/2025 2:00:00 PM
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday - Astera Labs ( NASDAQ:ALAB ) , Arista Networks ( NYSE:ANET ) 8/6/2025 2:42:00 PM
Sleep Apnea Devices Market is expected to generate a revenue of USD 14.59 Billion by 2031, Globally, at 10.42 % CAGR: Verified Market Research® 7/21/2025 2:00:00 PM
Are Options Traders Betting on a Big Move in LivaNova Stock? 6/25/2025 3:37:00 PM
Neurostimulation Devices Market Set to Reach US$ 11.83 Billion by 2030, Driven by Rising Neurological Disorders and Technological Advancements - The Insight Partners 3/28/2025 12:25:00 PM
Neurosurgery Market Size to Reach USD 6.8 Billion by 2034, Growing at 4.5% CAGR with Technological Advancements and Rising Focus on Personalized Medicine - Analysis by TMR 3/12/2025 2:02:00 PM
Neurology Devices Market is Expected to Reach USD 22,335.5 Million by 2035, Growing at 6.7% CAGR | Fact.MR Report 3/10/2025 11:30:00 AM
Teladoc Enhances Virtual Sitter With AI for Improved Care Delivery 11/26/2024 6:31:00 PM
Best Momentum Stocks to Buy for November 7th 11/7/2024 3:00:00 PM

Financial Details for LIVN

Company Overview

Ticker LIVN
Company Name LivaNova PLC
Country USA
Description LivaNova PLC (LIVN) is a global medical device company specializing in the design, development, manufacture, and sale of innovative therapeutic solutions, primarily focused on cardiac and neuromodulation therapies. Headquartered in London, UK, LivaNova leverages its advanced technology and expertise to address critical patient needs and improve outcomes in the fields of cardiology and neurology. With a commitment to quality and patient care, the company operates in multiple international markets, driving growth through strategic partnerships and product enhancements.
Sector Name HEALTHCARE
Industry Name MEDICAL DEVICES
Most Recent Quarter 6/30/2025
Next Earnings Date 10/29/2025

Stock Price History

Last Day Price 52.15
Price 4 Years Ago 87.43
Last Day Price Updated 10/8/2025 4:17:17 PM EST
Last Day Volume 263,471
Average Daily Volume 587,016
52-Week High 58.91
52-Week Low 32.48
Last Price to 52 Week Low 60.56%

Valuation Measures

Trailing PE N/A
Industry PE 44.24
Sector PE 41.70
5-Year Average PE 24.74
Free Cash Flow Ratio 4.80
Industry Free Cash Flow Ratio 37.96
Sector Free Cash Flow Ratio 30.25
Current Ratio Most Recent Quarter 1.29
Total Cash Per Share 10.87
Book Value Per Share Most Recent Quarter 20.57
Price to Book Ratio 2.49
Industry Price to Book Ratio 3.99
Sector Price to Book Ratio 32.02
Price to Sales Ratio Twelve Trailing Months 2.23
Industry Price to Sales Ratio Twelve Trailing Months 4.50
Sector Price to Sales Ratio Twelve Trailing Months 20.22
Analyst Buy Ratings 6
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 54,601,000
Market Capitalization 2,847,442,150
Institutional Ownership 104.27%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 2.34%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 65.90%
Annual Earnings Growth 260.39%
Reported EPS 12 Trailing Months -3.88
Reported EPS Past Year 1.93
Reported EPS Prior Year 3.37
Net Income Twelve Trailing Months -211,317,000
Net Income Past Year 63,234,000
Net Income Prior Year 17,546,000
Quarterly Revenue Growth YOY 10.70%
5-Year Revenue Growth 2.94%
Operating Margin Twelve Trailing Months 15.30%

Balance Sheet

Total Cash Most Recent Quarter 593,638,000
Total Cash Past Year 428,858,000
Total Cash Prior Year 266,504,000
Net Cash Position Most Recent Quarter 245,149,000
Net Cash Position Past Year -120,766,000
Long Term Debt Past Year 549,624,000
Long Term Debt Prior Year 568,543,000
Total Debt Most Recent Quarter 348,489,000
Equity to Debt Ratio Past Year 0.71
Equity to Debt Ratio Most Recent Quarter 0.76
Total Stockholder Equity Past Year 1,320,258,000
Total Stockholder Equity Prior Year 1,277,628,000
Total Stockholder Equity Most Recent Quarter 1,122,839,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 162,097,000
Free Cash Flow Per Share Twelve Trailing Months 2.97
Free Cash Flow Past Year 135,931,000
Free Cash Flow Prior Year 39,933,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.51
MACD Signal 0.01
20-Day Bollinger Lower Band 38.50
20-Day Bollinger Middle Band 49.35
20-Day Bollinger Upper Band 60.19
Beta 0.95
RSI 49.37
50-Day SMA 46.67
150-Day SMA 49.93
200-Day SMA 54.19

System

Modified 10/7/2025 3:39:55 AM EST